Giulia Oliva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Giulia Oliva has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Amanda Prince
Baylor College of Medicine, Houston, TX
1 shared publication - Damien A. Fair
Masonic Institute for the Developing Brain, University of Minnesota, Minneapolis, MN, USA
1 shared publication - Diana Takahashi
Oregon National Primate Research Center, Beaverton, OR
1 shared publication - Elinor L. Sullivan
Department of Psychiatry, Oregon Health & Science University, United States; Steven J. Sharp Center for Mental Health Innovation, Oregon Health & Science University, United States
1 shared publication - Gary J. Brenner
Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts
1 shared publication John J. Mekalanos
Harvard Medical School
1 shared publication
Latest Publications
- Open Access
- 1 August 2023
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 19 (2) , 2262639
Culture of attenuated Salmonella Typhimurium VNP20009 in animal-product-free media does not alter schwannoma growth control
Schwannomas are slow-growing benign peripheral nerve sheath tumors derived from Schwann-lineage cells that develop in association with NF2-related schwannomatosis (NF2) and schwannomatosis (NF3), as well as spontaneously. Individuals affected with NF2 and NF3 have multiple schwannomas with tumors arising throughout life. Surgical resection, the standard management, is limited in scope and efficacy and is itself associated with significant morbidity. We have previously shown that direct intratumoral injection of attenuated Salmonella Typhimurium (S. Typhimurium), strain VNP20009, showed a potent anti-tumor effect in preclinical NF-2 schwannoma models. The United States Federal Drug Administration (FDA) requires that bacterial products utilized in clinical trials be produced without exposure to animal-derived-products. In this context, we developed, characterized, and tested the antitumor efficacy of an attenuated S. Typhimurium serially passaged in animal-product-free media, naming it VNP20009-AF for “VNP20009-animal-product-free.” Our in vitro data did not indicate any significant changes in the viability, motility, or morphology of VNP20009-AF, compared to its parental strain. In vivo efficacy data demonstrated that VNP20009-AF and VNP20009 controlled tumor growth to the same degree in both human NF2-schwannoma xenograft and murine-NF2 schwannoma allograft models. Together, these data support the use of VNP20009-AF for the translation of bacterial schwannoma therapy into clinical trials.
- 1 August 2023
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 19 (2) , 2262639
Open AccessCulture of attenuated Salmonella Typhimurium VNP20009 in animal-product-free media does not alter schwannoma growth control
Schwannomas are slow-growing benign peripheral nerve sheath tumors derived from Schwann-lineage cells that develop in association with NF2-related schwannomatosis (NF2) and schwannomatosis (NF3), as well as spontaneously. Individuals affected with NF2 and NF3 have multiple schwannomas with tumors arising throughout life. Surgical resection, the standard management, is limited in scope and efficacy and is itself associated with significant morbidity. We have previously shown that direct intratumoral injection of attenuated Salmonella Typhimurium (S. Typhimurium), strain VNP20009, showed a potent anti-tumor effect in preclinical NF-2 schwannoma models. The United States Federal Drug Administration (FDA) requires that bacterial products utilized in clinical trials be produced without exposure to animal-derived-products. In this context, we developed, characterized, and tested the antitumor efficacy of an attenuated S. Typhimurium serially passaged in animal-product-free media, naming it VNP20009-AF for “VNP20009-animal-product-free.” Our in vitro data did not indicate any significant changes in the viability, motility, or morphology of VNP20009-AF, compared to its parental strain. In vivo efficacy data demonstrated that VNP20009-AF and VNP20009 controlled tumor growth to the same degree in both human NF2-schwannoma xenograft and murine-NF2 schwannoma allograft models. Together, these data support the use of VNP20009-AF for the translation of bacterial schwannoma therapy into clinical trials.
- Open Access
- 1 January 2016
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 214 (1) , S50
70: A high fat maternal diet contributes to microbiome-driven regulation of the offspring gut-brain axis & behavior in primates
- 1 January 2016
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 214 (1) , S50
Open Access70: A high fat maternal diet contributes to microbiome-driven regulation of the offspring gut-brain axis & behavior in primates